
Now that Gilead Sciences has won U.S. regulatory approval for its groundbreaking HIV prevention drug, the company has another hurdle to clear — ensuring the medicine can be accessed in low-income countries where the disease remains a stubborn problem.
As far as Gilead is concerned, the groundwork exists to meet that goal.
Last October, the drugmaker reached voluntary licensing agreements to eventually make lenacapavir available in 120 mostly low- and lower-middle-income countries. Then, the President’s Emergency Plan for AIDS Relief, or PEPFAR, and the Global Fund to Fight AIDS, Tuberculosis, and Malaria crafted an arrangement to cover dosing for 2 million people over three years in numerous poor countries.

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in